Cleared Traditional

K801873 - MODEL 86-21-0 260 SECONDARY MEDICATION

K801873 is the FDA 510(k) clearance for MODEL 86-21-0 260 SECONDARY MEDICATION by Y. It is a Class 2 General Hospital device (product code FPA) cleared through the Traditional 510(k) pathway after a 22-day FDA review.

K801873 · Y · General Hospital
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 1980
Decision
22d
Days
Class 2
Risk

K801873 is an FDA 510(k) clearance for the MODEL 86-21-0 260 SECONDARY MEDICATION. Classified as Set, Administration, Intravascular (product code FPA), Class II - Special Controls.

Submitted by Y (Mchenry, US). The FDA issued a Cleared decision on August 27, 1980 after a review of 22 days - a notably fast clearance cycle.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.5440 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Y devices

Submission Details

510(k) Number K801873 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 05, 1980
Decision Date August 27, 1980
Days to Decision 22 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
107d faster than avg
Panel avg: 129d · This submission: 22d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code FPA Set, Administration, Intravascular
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 880.5440
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General Hospital devices follow this clearance model.

Regulatory Peers - FPA Set, Administration, Intravascular

All 470
Devices cleared under the same product code (FPA) and FDA review panel - the closest regulatory comparables to K801873.
NITROGLYCERINE IV SET
K810317 · Abbott Laboratories · May 1981
PRIMARY SOLUTION ADMIN. SET-#86-01-0 260
K801871 · Y · Aug 1980
MODEL 86-01-1 260 SOLUTION ADMIN. SET
K801872 · Y · Aug 1980
MODEL 86-21-1 260 APPROX. 60 DROPS/VENTD
K801874 · Y · Aug 1980
MCGRAW I.V. ADMINISTRATION SET
K801540 · American Hospital Supply Corp. · Aug 1980
MODEL 72-81-0 UNVENTED SOLUTION ADM. SET
K801613 · Y · Aug 1980